1,1-二己基肼 | 20240-69-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1,1-二己基肼
• 英文名称: N,N-dihexyl-hydrazine
• 英文别名: N,N-Dihexyl-hydrazin；N,N-Di-n-hexylhydrazin；1,1-Dihexylhydrazine
• CAS: 20240-69-1
• 化学式: C₁₂H₂₈N₂
• 分子量: 200.368
• InChiKey: HYRPLOVLRXZKMI-UHFFFAOYSA-N

物化性质

• 沸点：
  286.7±9.0 °C(Predicted)
• 密度：
  0.843±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  14
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,1-二己基肼 、 苯甲酰氯 在 三乙胺 作用下， 以 苯 为溶剂， 生成 N′,N′-bis(1-hexyl)benzohydrazide
  参考文献：
  名称：

  Pyrolysis of 1,1-dihexyl-1-methylamine-2-acylimides

  摘要：

  DOI：

  10.1021/jo00810a007
• 作为产物：
  描述：

  1-氯己烷 在 乙醇 、 肼 作用下， 生成 己基肼 、 1,1-二己基肼
  参考文献：
  名称：

  Westphal, Chemische Berichte, 1941, vol. 74, p. 775

  摘要：

  DOI：

文献信息

• NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF
  申请人：Ochiai Hiroshi

  公开号：US20090233908A1

  公开（公告）日：2009-09-17

  A compound represented by formula (I): (wherein the symbols are the same as defined in the description), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof, and medicinal use thereof. The compound represented by formula (I) has CXCR4 antagonistic activity. It is hence useful as, e.g., a preventive and/or therapeutic agent for CXCR4-mediated diseases such as inflammatory/immunologic diseases (e.g., rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, and rejection reactions of transplanted organs), allergic diseases, infections diseases (e.g., human immunodeficiency virus infection and acquired immunologic deficiency syndrome), psychoneurotic diseases, cerebral diseases, cardiac/vascular disease, metabolic diseases, cancer diseases (e.g., cancer, cancer metastasis) or as an agent for regeneration therapy.

  化合物的化学式为（I）：（其中符号的定义与说明书中相同），其盐，N-氧化物，溶剂化合物或前药，以及其药用。化合物（I）具有CXCR4拮抗活性。因此，它可用作预防和/或治疗CXCR4介导疾病的药物，例如炎症/免疫疾病（例如类风湿性关节炎，关节炎，视网膜病变，肺纤维化和移植器官的排斥反应），过敏性疾病，感染性疾病（例如人类免疫缺陷病毒感染和获得性免疫缺陷综合症），心理神经疾病，脑部疾病，心血管疾病，代谢性疾病，癌症（例如癌症，癌症转移）或再生治疗剂。
• Flame retardant compositions
  申请人：Ronan Nicolas

  公开号：US20070029531A1

  公开（公告）日：2007-02-08

  The present invention is directed to a method of flame retarding a polymeric substrate using a specific group of azo and peroxide derivatives as flame retardants, to flame retardant compositions as well as to novel azo compounds usable as flame retarding compounds.

  本发明涉及一种使用特定的偶氮和过氧化物衍生物作为阻燃剂的聚合物基材的阻燃方法，以及阻燃组合物和可用作阻燃化合物的新型偶氮化合物。
• Compound Containing Basic Group and Use Thereof
  申请人：Kokubo Masaya

  公开号：US20080009495A1

  公开（公告）日：2008-01-10

  The present invention relates to a compound represented by formula (I-0): wherein symbols in formula have the same meanings as described in the present specification, a salt thereof, an N-oxide thereof or a solvate thereof or a prodrug thereof, and medical use thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.

  本发明涉及一种由式（I-0）表示的化合物：其中，式中的符号与本说明书中所述的意义相同，其盐，N-氧化物或溶剂化物或其前药，以及其医学用途。本发明的化合物具有对CXCR4的拮抗活性，因此可用作预防和/或治疗CXCR4介导的疾病的药物，例如，炎症和免疫性疾病（例如，类风湿性关节炎，关节炎，视网膜病变，肺纤维化，移植器官排斥等），过敏性疾病，感染（例如，人类免疫缺陷病毒感染，获得性免疫缺陷综合症等），精神神经疾病，脑部疾病，心血管疾病，代谢性疾病和癌症性疾病（例如，癌症，癌症转移等），或作为再生疗法的药物。
• CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF
  申请人：Kokubo Masaya

  公开号：US20120207765A1

  公开（公告）日：2012-08-16

  A compound represented by general formula (I): a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiac/vascular disease (for example, arteriosclerosis, myocardial infarction, stenocardia, cerebral infarction, chronic arterial occlusive disease, etc.), metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), a preventive and/or therapeutic agent for cancerous diseases or infections, or an agent for regeneration therapy.

  通式（I）所代表的化合物：其盐、溶剂化物或前药物，其中所有符号均如规范中所定义，具有对CXCR4的拮抗活性，因此可用作预防和/或治疗CXCR4介导的疾病，例如炎症和免疫性疾病（例如类风湿性关节炎、关节炎、系统性红斑狼疮、视网膜病变、黄斑变性、肺纤维化、移植器官排斥等）、过敏性疾病、感染（例如人类免疫缺陷病毒感染、获得性免疫缺陷综合症等）、心理神经疾病、脑部疾病、心脏/血管疾病（例如动脉硬化、心肌梗死、心绞痛、脑梗死、慢性动脉闭塞性疾病等）、代谢性疾病和癌症性疾病（例如癌症、癌症转移等），是用于癌症性疾病或感染的预防和/或治疗剂，或再生疗法的剂。
• LATENT CURING AGENTS, EPOXY RESIN COMPOSITIONS CONATING THE SAME, SEALING MATERIALS, AND ORGANIC EL DISPLAYS
  申请人：Mitsui Chemicals, Inc.

  公开号：EP2199313A1

  公开（公告）日：2010-06-23

  The invention aims to provide latent curing agents which exert high low-temperature curing properties when used together with ionically polymerizable compounds and which exhibit high storage stability at room temperature. Latent curing agents for ionically polymerizable compounds which agents each contain a hydroxyl-free amine imide compound having an N-N bond energy of 100 to 210 kJ/mol as determined by B3LYP functional theory method.

  本发明旨在提供与离子可聚合化合物一起使用时具有较高低温固化性能，并且在室温下具有较高储存稳定性的潜在固化剂。用于离子可聚合化合物的潜在固化剂，每种固化剂都含有一种无羟基胺亚胺化合物，根据 B3LYP 功能理论方法测定，其 N-N 键能量为 100 至 210 kJ/mol。